We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




ViaCell Obtains License to Oocyte Cryopreservation

By Biotechdaily staff writers
Posted on 29 Aug 2003
A worldwide license for the use of technology to cryopreserve unfertilized human oocytes has been obtained by ViaCell, Inc. More...
(Boston, MA, USA) from Gamete Technology, Inc. (N. Kingston, RI, USA) and Massachusetts General Hospital (MGH, Boston, USA).

The patented technology is designed to help freeze, store, and later fertilize oocytes for use in in vitro fertilization (IVF) around the world. The technology is the result of an eight-year development effort led by scientists at MGH. By freezing eggs before cancer treatment or earlier in life when egg quality is higher, a woman may be able to retain her ability to become pregnant and have a child many months or even years later. ViaCell also offers umbilical cord blood stem cell preservation services through a subsidiary called Viacord.

"This agreement with Gamete Technology positions ViaCell as a leader in the development of oocyte cryopreservation services, which has the clear potential to be one of the most significant advances in reproductive medicine since the introduction of IVF,” said Marc Beer, chairman and CEO of ViaCell.





Related Links:
ViaCell
Massachusetts General Hospital

New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Automatic CLIA Analyzer
Shine i6000
New
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.